Forecasting The Future: 6 Analyst Projections For Chemed

Throughout the last three months, 6 analysts have evaluated Chemed (NYSE:CHE), offering a diverse set of opinions from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	2	3	1	0	0
Last 30D	1	0	0	0	0
1M Ago	0	0	0	0	0
2M Ago	0	2	1	0	0
3M Ago	1	1	0	0	0

Insights from analysts' 12-month price targets are revealed, presenting an average target of $584.83, a high estimate of $650.00, and a low estimate of $500.00. Observing a downward trend, the current average is 7.52% lower than the prior average price target of $632.40.

Analyzing Analyst Ratings: A Detailed Breakdown

A clear picture of Chemed's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Brian Tanquilut	Jefferies	Raises	Buy	$550.00	$490.00
Ben Hendrix	RBC Capital	Lowers	Outperform	$589.00	$640.00
Michael Wiederhorn	Oppenheimer	Lowers	Outperform	$580.00	$650.00
Brian Tanquilut	Jefferies	Announces	Hold	$500.00	-
Ben Hendrix	RBC Capital	Lowers	Outperform	$640.00	$674.00
Joanna Gajuk	B of A Securities	Lowers	Buy	$650.00	$708.00

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Chemed. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Chemed compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Chemed's stock. This comparison reveals trends in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Chemed's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Chemed analyst ratings.

Discovering Chemed: A Closer Look

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

Chemed: Delving into Financials

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Over the 3M period, Chemed showcased positive performance, achieving a revenue growth rate of 3.85% as of 30 June, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Chemed's net margin excels beyond industry benchmarks, reaching 8.48%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Chemed's ROE excels beyond industry benchmarks, reaching 4.41%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Chemed's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.05%, the company showcases efficient use of assets and strong financial health.

Debt Management: With a below-average debt-to-equity ratio of 0.12, Chemed adopts a prudent financial strategy, indicating a balanced approach to debt management.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.